neurology

News

Janssen J&J Johnson and Johnson pharmaceutical companies

J&J unveils top pipeline prospects, with main focus on cance...

Johnson & Johnson has shone the spotlight on the most promising drugs in its pipeline, saying it plans to file 10 major drugs between now and 2023.

News

German Merck shows new data backing BTK drug evobrutinib in ...

Germany’s Merck KGaA has announced new mid-stage data that it says support further studies into its BTK inhibitor drug evobrutinib in multiple sclerosis, which could provide patients with a

News

NICE backs Ocrevus for PPMS in England - but with caveats

Patients with a severe progressive form of multiple sclerosis will get access to the first licensed treatment for the condition after NICE recommended regular NHS funding for Roche's Ocrevu

News

Biogen's R&D strategy fails to impress after Alzheimer's tri...

The dust has settled at Biogen following the company’s disastrous announcement that it was ending development of Alzheimer’s drug aducanumab, and in its latest Q1 figures the company hoped

News

Illustration of a nerve cell on a colored background with light effects

Alder gears up for migraine showdown with eptinezumab filing

Alder BioPharmaceuticals has filed its migraine drug eptinezumab with the US regulator, the last in a gang of four CGRP-class antibodies developed to treat the condition.

News

European regulator restricts use of Sanofi MS drug Lemtrada

The European drug regulator has called for a review of Sanofi’s multiple sclerosis drug Lemtrada following reports of immune-related conditions and sometimes fatal problems with the heart a

J&J unveils top pipeline prospects, with main focus on cance...

German Merck shows new data backing BTK drug evobrutinib in ...

NICE backs Ocrevus for PPMS in England - but with caveats

Biogen's R&D strategy fails to impress after Alzheimer's tri...

Alder gears up for migraine showdown with eptinezumab filing

European regulator restricts use of Sanofi MS drug Lemtrada

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

neurology

Editor's Picks